Message Font: Serif | Sans-Serif
No. of Recommendations: 1
There hasn't been too much in the news lately, but there was an article in Discover Magazine back in January (right before they took off). Basically if TRMS can continue the amazing progress they have thus far on inhibiting HIV, the sky is the limit for the stock. I believe the only drawback so far is that the treatment is a protein base, and must be injected twice a day. It couldn't hurt to sell now, but why?

Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.